Quadrant Capital Group
ESPR icon

Quadrant Capital Group’s Esperion Therapeutics ESPR Stock Holding History

Quadrant Capital Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-281
Closed -$770 – 1662
2026
Q1 		$770 Hold
281
– – ﹤0.01% 2608
2025
Q4 		$1.04K Hold
281
– – ﹤0.01% 2595
2025
Q3 		$745 Buy
+281
New +$543 ﹤0.01% 2578
2025
Q1 		– Sell
-735
Closed -$1.62K – 2774
2024
Q4 		$1.62K Hold
735
– – ﹤0.01% 2524
2024
Q3 		$1.21K Buy
735
+300
+69% +$606 ﹤0.01% 2565
2024
Q2 		$966 Buy
+435
New +$1.02K ﹤0.01% 2568
2023
Q2 		– Sell
-386
Closed -$614 – 2714
2023
Q1 		$614 Sell
386
-573
-60% -$2.96K ﹤0.01% 2580
2022
Q4 		$5.97K Sell
959
-554
-37% -$3.96K ﹤0.01% 2166
2022
Q3 		$10K Buy
1,513
+844
+126% +$5.8K ﹤0.01% 1886
2022
Q2 		$4K Buy
669
+549
+458% +$3.11K ﹤0.01% 2027
2022
Q1 		$1K Buy
120
+13
+12% +$56 ﹤0.01% 2289
2021
Q4 		$1K Buy
+107
New +$857 ﹤0.01% 2291
2021
Q3 		– Sell
-21
Closed – – 2536
2021
Q2 		$0 Buy
+21
New +$506 ﹤0.01% 2446
2016
Q3 		– Sell
-377
Closed -$3K – 2016
2016
Q2 		$3K Buy
+377
New +$6.25K ﹤0.01% 1336

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Quadrant Capital Group's ESPR Position: Q2 2026 in Review

Quadrant Capital Group sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 281 shares — an estimated $770 sold.

Quadrant Capital Group first reported a position in ESPR in Q2 2016 and held it in 14 quarters. The position peaked at $10K in Q3 2022. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Quadrant Capital Group reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 281 Esperion Therapeutics shares in Q2 2026, an estimated $770.
  • Quadrant Capital Group first reported a position in Esperion Therapeutics in Q2 2016 and held it in 14 quarters.
  • Quadrant Capital Group's Esperion Therapeutics position peaked at $10K in Q3 2022.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.